Online inquiry

IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1305MR)

This product GTTS-WQ1305MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets RGMA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001166283.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 56963
UniProt ID Q96B86
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1305MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1822MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ1847MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ9290MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ5452MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ11775MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ9839MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ7561MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ2581MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW